Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Anistreplase
open-in-new
<h2 id="uses">Uses</h2> <p>Anistreplase is used to treat <a href="/facts/Blood_clots/vH6FDIQG">blood clots</a> in emergency situations such as <a href="/facts/Myocardial_infarction/xoGw0qcG">myocardial infarction</a>.<a class="footnote-ref" id="fnref:1" href="#fn:1"><sup>1</sup></a> Early treatment gives better outcomes.<a class="footnote-ref" id="fnref:2" href="#fn:2"><sup>2</sup></a> </p> <h2 id="history">History</h2> <p>Anistreplase has been developed by <a href="/facts/Beecham_(pharmaceutical_company)/SN7wXHx9">Beecham</a> under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.<a class="footnote-ref" id="fnref:3" href="#fn:3"><sup>3</sup></a><a class="footnote-ref" id="fnref:4" href="#fn:4"><sup>4</sup></a><a class="footnote-ref" id="fnref:5" href="#fn:5"><sup>5</sup></a> </p> <h2 id="references">References</h2> <ol> <li id="fn:1"><p>Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585. <a href="https://www.bmj.com/content/312/7025/212.full" target="_blank">https://www.bmj.com/content/312/7025/212.full</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></p></li> <li id="fn:2"><p>Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585. <a href="https://www.bmj.com/content/312/7025/212.full" target="_blank">https://www.bmj.com/content/312/7025/212.full</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></p></li> <li id="fn:3"><p>Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585. <a href="https://www.bmj.com/content/312/7025/212.full" target="_blank">https://www.bmj.com/content/312/7025/212.full</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></p></li> <li id="fn:4"><p>Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (April 1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1239197" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1239197</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></p></li> <li id="fn:5"><p>Rawles J, Light J (October 1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1059832" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1059832</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></p></li> </ol>